AddedRisk Factors
•the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
•unforeseen safety issues, undesirable side effects, or other unexpected characteristics; and
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
and supportive studies that we consider appropriate and the results are positive, we may not receive regulatory approval and marketing authorization to market our product candidates, which would adversely affect our business, financial condition, results of operations and prospects. Following regulatory approval, there is no assurance of commercial success.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, the FDA and comparable foreign regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. There remains substantial uncertainty as to how the current U.S. administration will seek or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. State governments may also attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. This uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates. Such policy or regulatory changes through, for example, executive orders or legislation could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
Osilodrostat and levoketoconazole have been designated orphan drugs in both the EU and the United States.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
•delays or inability to obtain institutional review board (“IRB”) approval at prospective trial sites;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Short sellers have, and likely will continue to, attempt to drive down the price of our common stock. Short selling is the practice of selling stock the seller does not own with the intention of buying it back later at a lower price, thereby profiting
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
as the U.S. Department of Health and Human Services Office of Civil Rights issued a proposed rule that would amend certain security compliance requirements for covered entities and business associates.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
Since 2012, a medication owned by Recordati-S.p.A. has marketed the Italian pharmaceutical company Recordati-S.p.A., the injectable somatostatin analogue Signifor® (pasireotide) Injection, has been marketed pasireotide in both the United States and the EU as a treatment for adult patients with Cushing’s disease (a disease, a subset of hypercortisolism). hypercortisolism.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
On March 6, In 2020, the FDA granted Recordati approval to market another the cortisol synthesis inhibitor, Isturisa® (osilodrostat) tablets, inhibitor osilodrostat to treat patients with Cushing’s disease. disease, which approval was broadened in April 2025 to include adult patients with any etiology of hypercortisolism.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The availability of generic versions of Korlym from Sun or Hikma could materially harm our results of operations and financial condition, even if our on-going appeal against Teva is successful and Teva, Sun and Hikma were required to withdraw their products and pay us damages. condition.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure by us or our vendors to comply with new laws or regulations, whether by us regulations or by our vendors, as well as to respond in a timely way to abrupt changes in the application of existing laws and regulations, regulations could adversely affect our operations, cash flow and financial condition or otherwise harm our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, certain state laws govern the privacy and security of health health-related and other personal information in certain circumstances, some of which are may be more stringent stringent, broader in scope or offer greater individual rights with respect to protected health information than HIPAA and many of which may differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, the California Consumer Privacy Act, which took effect on January 1, 2020, and was later Act (the “CCPA”), revised and expanded amended by the California Privacy Rights Act, collectively Act (the “CPRA” and collectively, the CCPA, “CCPA”), created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain personal information as well as limitation on data uses, audit requirements for higher risk data, and opt outs for certain uses of sensitive data.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The imposition of tariffs such as the administration has threatened to impose on materials we or our vendors and collaborators use to conduct experiments or to make our Products or product candidates would have increased our costs and may increase our cost of doing business. them further.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Beginning in 2025, the The IRA also shifts a significant portion of the Medicare beneficiary costs from the government and beneficiaries to manufacturers. manufacturers in the form of limitations on price increases and rebates paid to the government.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue for the preceding financial year or €20 million, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, if Optime Curant has operational difficulties or otherwise becomes unable or unwilling to perform its obligations under our agreement, we may not be able to dispense our Products in a timely manner to some or all of our patients. patients, which may adversely affect our business, results of operations and financial position.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we elect, or are required by authorities, to delay, suspend or terminate a clinical trial or commercialization efforts, the commercial prospects of the affected product candidates or products may be harmed and our ability to generate product revenues from them may be delayed or eliminated.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If Teva’s commercial efforts are successful, they may materially harm our results of operations and financial condition, even if our appeal is successful and Teva is required to withdraw its product and pay us damages. condition.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If In addition, if we receive regulatory approval for a product candidate, we will be subject to ongoing requirements and oversight by the FDA and other regulatory authorities, such as continued safety and other reporting requirements and possibly post-approval marketing restrictions and additional costly clinical trials.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
CATALYST’s results were published in Diabetes Care (Buse et al., April 2025 (first phase) and DeFronzo et al., June 2025 (second phase)), the peer-reviewed journal of the American Diabetes Association.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
To determine the prevalence of hypercortisolism in patients with resistant hypertension, we initiated the MOMENTUM trial in March 2025. Resistant hypertension is defined by the American Heart Association as systolic blood pressure greater than 130mm Hg and diastolic blood pressure greater than 80mm Hg despite the use of three or more antihypertensive medications of different classes, including a diuretic. MOMENTUM completed enrollment of over 1,000 patients in December 2025. Enrollment is closed.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
On December 30, 2025, the FDA issued a CRL declining to approve relacorilant. While the letter acknowledged that our GRACE trial had met its primary endpoint and that our GRADIENT trial had provided confirmatory evidence, the FDA stated that additional evidence of efficacy would be required for approval. We are working with the FDA to determine relacorilant’s optimal path to approval.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Relacorilant in Combination with Chemotherapy. In July 2025, we submitted an NDA seeking approval to market relacorilant plus the chemotherapy medication nab-paclitaxel as a treatment for patients with platinum-resistant ovarian cancer in the United States. In September 2025, the FDA accepted our NDA for filing and assigned a PDUFA date of July 11, 2026. In October 2025, we submitted an MAA to the EMA seeking approval in the European Union. Our NDA and MAA are both based on positive results from our pivotal Phase 3 ROSELLA and Phase 2 trials, in which patients exhibited clinically meaningful improvements in PFS and OS. In both trials, relacorilant was well-tolerated and did not increase the safety burden of patients who took it.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
ROSELLA met its dual primary endpoints – PFS as assessed by blinded independent central review and OS. In March 2025, we announced that ROSELLA had met its PFS endpoint. Patients treated with relacorilant in addition to nab-paclitaxel experienced a clinically and statistically significant 30 percent reduction in risk of disease progression compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008). PFS improvement as assessed by ROSELLA’s clinical investigators was also positive (hazard ratio: 0.71; p-value: 0.0030). In January 2026, we announced that ROSELLA had met its OS primary endpoint. Patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a clinically and statistically significant 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.65; p-value: 0.0004). The median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone. Importantly, both PFS and OS benefits were seen in all clinically relevant patient subgroups, including those with poor prognoses.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Relacorilant in combination with nab-paclitaxel was well-tolerated, consistent with its known safety profile. Importantly, relacorilant conferred its benefit without increasing the safety burden of the patients who received it. The type, frequency and severity of adverse events in the combination arm were comparable to those in the nab-paclitaxel monotherapy arm.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The results from ROSELLA were published in The Lancet (Olawaiye et al., June 2025).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In April 2025, we initiated a Phase 2 trial, BELLA, which has three parts. In December 2025, Part A completed enrollment of 95 patients with platinum-resistant ovarian cancer. Part A will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and bevacizumab. Part B has a planned enrollment of 90 patients with platinum-sensitive ovarian cancer, whose disease had progressed while receiving treatment with a PARP-inhibitor. Part B will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and bevacizumab. Part C has a planned enrollment of 90 patients with endometrial cancer who have received one or two prior lines of therapy. Part C will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we initiated a Phase 2 trial, TRIDENT, with a planned enrollment of 50 patients with pancreatic cancer, who have not received prior therapy for metastatic disease. TRIDENT will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and gemcitabine.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In collaboration with the Paris-based academic research cooperative ARCAGY-GINECO, we will initiate, in the first quarter of 2026, a Phase 2 trial, STELLA, in 50 patients with cervical cancer, who have received one or two prior lines of therapy. STELLA will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The EC has designated relacorilant as an orphan drug for the treatment of ovarian and pancreatic cancers.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Nenocorilant in Combination with Immunotherapy. Immunotherapy harnesses the body’s immune system to identify and destroy cancer cells. We are testing the potential of our proprietary, selective cortisol modulator, nenocorilant to treat cancer by reducing cortisol-activated immune suppression and thereby help the patient’s immune system reduce or eradicate tumors while
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
Relacorilant in Patients with Adrenal Cancer with Cortisol Excess. We have completed an open-label, Phase 1b trial of relacorilant plus the PD-1 checkpoint inhibitor pembrolizumab in 14 patients with metastatic or unresectable adrenal cancer whose tumors produce cortisol. Patients with this form of adrenal cancer virtually never respond to immunotherapy and their disease progresses very rapidly. Our trial sought to test whether adding relacorilant to pembrolizumab therapy would reduce cortisol-activated immune suppression sufficiently to help the patient’s immune system reduce or eradicate the patient’s tumors while also reducing the symptoms of hypercortisolism caused by the tumors’ hypersecretion of cortisol. Although patients exhibited significant improvements in their symptoms of hypercortisolism, such as reductions in hypertension and hyperglycemia, their tumor progression did not slow. The combination of relacorilant with pembrolizumab was well-tolerated. We are evaluating next steps to better understand the role cortisol modulation may play in combination with immunotherapies directed to other tumor types and earlier stages of cancer.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
In the year ended December 31, 2024, 2025, we spent $38.0 $245.9 million acquiring shares of our common stock, comprised of $15.7 $172.9 million pursuant to our Stock Repurchase Program, $17.0 $56.8 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options and $5.3 $16.1 million to satisfy tax withholding requirements from vesting of restricted stock grants, offset by $5.5 million received in connection with our ESPP and $4.2 million net cash received from the exercise of stock options.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to increased spending on expenses related to the advancement and completion of our Cushing’s syndrome and Oncology development programs and increased employee compensation expense expenses, partially offset by decreased expenses related to support these activities. development programs that are nearing completion.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase change in income tax expense for the year ended December 31, 2024 2025 resulting in an income tax benefit compared to 2023 an income tax expense in 2024 was primarily due to increased income before income taxes. stock compensation deductions and decreased pretax income.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The change for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to investments in marketable securities during 2024 compared to a higher allocation of cash proceeds from maturities of marketable securities towards cash equivalents to purchase shares in anticipation of the closing of connection with our tender offer during 2023. Stock Repurchase Program.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our research and development expense to be higher in 2025 2026 than in 2024 2025 as our clinical programs advance and we add initiate new clinical trials, assuming success in our existing trials, and our existing trials enroll more patients. trials.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to increased sales and marketing activities and employee compensation expenses to support commercialization of our existing and sales and marketing activities. potential future products.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Women with a history of tumors that do not respond to initial platinum-based treatments (i.e., women with “primary platinum-refractory” disease) and those who have received more than three prior lines of therapy were excluded.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to lower net income resulting from higher revenue. operating expenses to support increased sales and marketing activities.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In For the year ended December 31, 2024, we spent $38.0 million acquiring shares of our common stock, comprised of $15.7 million pursuant to our Stock Repurchase Program, $17.0 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options options, $15.7 million pursuant to our Stock Repurchase Program and $5.3 million to satisfy tax withholding requirements from vesting of restricted stock grants, offset by $5.5 million received in connection with our ESPP and $4.2 million net cash received from the exercise of stock options.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Notably, As was the case in ROSELLA, the addition of relacorilant to treatment with nab-paclitaxel did not create an additional adverse event burden for patients. increase patients’ safety burden.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase of cost of sales as a percentage of revenue for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to increased manufacturing and distribution costs. a decrease in the average selling price of our Products.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Patients in GRADIENT who received relacorilant exhibited clinically meaningful and statistically significant improvements in a wide array of hypercortisolism’s signs and symptoms, including hypertension, hyperglycemia, weight and body composition compared to baseline, composition, while patients who received placebo did not.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new